Pacira BioSciences, Inc.

NASDAQ:PCRX

Drug Manufacturers - Specialty & Generic

Healthcare
$36.48 -0.79%

-$0.18 today

Market cap
$1.46B
Beta
0.29
P/E (TTM)
176.9
EPS (TTM)
$0.13
52W Low $18.80High $27.64

Volume 1.81M

Average 0.57M

PCRX Income Before Tax

Profit after all operating and non-operating items but before income tax.

Pacira BioSciences, Inc.NASDAQ: PCRX

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax dips below year-ago levels

Q1 FY2026 income before tax of $5M fell 42.6% year over year, behind the +119.4% change in trailing-twelve-month income before tax. Sequentially, it rose 775.3% from the prior quarter. Over 3 fiscal years it compounded at +8.3% a year.

Context

  • Income before tax amounted to 2.3% of revenue in FY2025, down 6.7 pp from a year earlier.
  • Income before tax increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -42.6% toward the trailing-twelve-month pace of +119.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5M+775.3% QoQ
Last fiscal yearDec 2025
$16.87M+126.7% YoY
LTMMar 2026
$13.17M+119.4% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-42.6%——
1 year+126.7%——
3-year CAGR+8.3%——
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
16.87M USD
Year-over-year change
+126.7%
4-year CAGR
-26.0%

Income Before Tax vs competitors

How PCRX compares with its peers on the latest reported figures

  • PCRX's LTM Mar 2026 income before tax of $13.17M is the 2nd highest of the 4 companies compared; the peer median is -$123.47M.
  • Its year-over-year change of +119.4% is the highest of 4, against a peer median of -250.3%.
  • Income before tax amounts to 1.8% of revenue for PCRX, versus a peer median of 14.9%.
PCRX Competitors Peer median
Income Before Tax for PCRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
COLLCollegium Pharmaceutical, Inc.LTM Mar 2026$108.24M +66.3%—13.6%
PCRXPacira BioSciences, Inc.LTM Mar 2026$13.17M +119.4%+8.3%1.8%
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026-$123.47M -250.3%—14.9%
SCLXScilex Holding CompanyLTM Mar 2026-$393.6M -428.2%—1162.4%
LTGOLatigo Biotherapeutics Inc.—— ———
Peer median (excluding PCRX) -$123.47M-250.3%—14.9%

Competitors are the stored peer set for PCRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue541.53M666.82M674.98M700.97M726.41M
Cost of Revenue140.26M199.3M184.67M170.43M149.75M
Gross Profit401.28M467.53M490.31M530.54M576.66M
Gross Margin74.1%70.1%72.6%75.7%79.4%
Research & Development55.55M84.8M76.26M81.58M117.31M
Selling, General & Admin199.35M254.52M269.44M294.1M368.76M
Operating Expenses311.35M407.5M402.63M603.91M543.36M
Depreciation & Amortization28.55M91.5M75.57M78.79M91.02M
EBITDA113.95M140.38M154.59M29.12M122.5M
EBITDA Margin21.0%21.1%22.9%4.2%16.9%
Operating Income89.92M60.02M87.68M(73.37M)33.3M
Operating Margin16.6%9.0%13.0%-10.5%4.6%
Interest Income896K4.54M11.44M19.69M22.73M
Interest Expense29M35.58M17.31M16.57M14.61M
Other Income / Expenses(33.52M)(46.72M)(25.97M)10.27M(16.43M)
Income Before Tax56.4M13.3M61.7M(63.11M)16.87M
Pre-Tax Margin10.4%2.0%9.1%-9.0%2.3%
Income Tax Expense14.42M(2.61M)19.75M36.45M9.84M
Net Income41.98M15.91M41.96M(99.56M)7.03M
Net Margin7.8%2.4%6.2%-14.2%1.0%
EPS (Basic)0.950.350.91(2.15)0.16
EPS (Diluted)0.920.340.89(2.15)0.16
Weighted Avg Shares44.26M45.52M46.22M46.25M44.57M
Weighted Avg Shares (Diluted)45.63M46.54M51.98M46.25M45.04M

Pacira BioSciences, Inc.

NASDAQ:PCRX

Intrinsic Alpha fair value

Locked

Current Price

$36.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.